Selling, General, and Administrative Costs: Biogen Inc. vs Wave Life Sciences Ltd.

A Tale of Two Biotech Giants: Biogen Inc. vs. Wave Life Sciences Ltd.

In the ever-evolving world of biotechnology, understanding the financial health of companies is crucial. This chart provides a fascinating glimpse into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Biogen Inc. and Wave Life Sciences Ltd., from 2014 to 2023.

Biogen Inc., a leader in neurological therapies, consistently outpaces Wave Life Sciences in SG&A expenses, reflecting its expansive operations and market reach. Over the past decade, Biogen's SG&A costs have grown by approximately 14%, peaking in 2021. In contrast, Wave Life Sciences, a smaller entity focused on genetic medicines, has seen its SG&A expenses surge by over 1,600%, highlighting its aggressive growth strategy.

This financial narrative underscores the contrasting scales and strategies of these biotech firms, offering insights into their operational priorities and market positioning.